KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to -$2.0 billion.

  • Teva Pharmaceutical Industries' Income from Continuing Operations rose 209.92% to $432.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $658.0 million, marking a year-over-year increase of 125.84%. This contributed to the annual value of -$2.0 billion for FY2024, which is 217.67% down from last year.
  • As of FY2024, Teva Pharmaceutical Industries' Income from Continuing Operations stood at -$2.0 billion, which was down 217.67% from -$617.0 million recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Income from Continuing Operations ranged from a high of $447.0 million in FY2021 and a low of -$4.2 billion during FY2020.
  • Its 3-year average for Income from Continuing Operations is -$1.7 billion, with a median of -$2.0 billion in 2024.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Income from Continuing Operations soared by 110.55% in 2021 and then crashed by 663.76% in 2022.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Income from Continuing Operations stood at -$4.2 billion in 2020, then skyrocketed by 110.55% to $447.0 million in 2021, then plummeted by 663.76% to -$2.5 billion in 2022, then soared by 75.52% to -$617.0 million in 2023, then crashed by 217.67% to -$2.0 billion in 2024.